Vaginismus Treatment in India
Get Vaginismus Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Vaginismus Treatment in UAE
Vaginismus Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Vaginismus is an involuntary, often distressing condition in which the pelvic floor musculature contracts reflexively, making vaginal penetration painful or impossible; it responds well to structured, multidisciplinary therapy with success rates exceeding 80–95% when evidence-based protocols are followed. GAF Healthcare coordinates treatment across India's NABH- and JCI-accredited centers and the UAE's JCI- and DHA-licensed hospitals, giving international patients access to specialist pelvic-floor physiotherapists, psychosexual counselors, and gynecologists under one coordinated care pathway. Patients travel to both destinations for the combination of world-class clinical expertise, shorter waiting times, significant cost savings over Western markets, and end-to-end logistical support provided by GAF Healthcare's dedicated case managers.
Hospital Stay: 0–1 days (treatment is overwhelmingly outpatient or day-care; brief overnight admission only if botulinum toxin injection under sedation is performed) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (depending on treatment modality: behavioral/physiotherapy programs typically allow flying after the final in-person session; botulinum toxin injection patients are cleared to fly in 5–7 days post-procedure once initial follow-up is complete) • Success Rate: 80–95% (combined behavioral, physiotherapy, and pharmacological protocols; highest rates achieved with integrated multidisciplinary programs)
What Is It?
Vaginismus — classified in DSM-5 and ICD-11 under Genito-Pelvic Pain/Penetration Disorder (GPPPD) — is characterized by persistent or recurrent difficulty with vaginal penetration accompanied by involuntary tensioning of the pelvic floor musculature, most critically the levator ani and bulbocavernosus groups. The reflex contraction is mediated by a complex interaction between the somatic nervous system, the autonomic fear-avoidance response, and conditioned psychological associations; it is not a structural anatomical defect. Severity is clinically graded using the Lamont Classification (Grade 1 through 5), with Grade 1 representing spasm only on examination and Grade 5 representing total avoidance of any pelvic contact, allowing clinicians to calibrate treatment intensity objectively.
The physiological impact extends well beyond sexual function. Chronic pelvic floor hypertonicity can produce secondary dyspareunia, urinary urgency or frequency due to puborectalis overactivation, chronic low-back and sacroiliac referred pain, and significant psychosocial sequelae including depression, relationship distress, and impaired quality of life. Inability to undergo routine gynecological examination or Pap smears also creates gaps in preventive care, making timely treatment a broader women's-health imperative.
The contemporary standard of care is multimodal and non-surgical in the majority of cases. First-line management combines cognitive-behavioral therapy (CBT) or acceptance and commitment therapy (ACT) with structured pelvic-floor physical therapy, systematic desensitization using graded vaginal dilators (silicone sets ranging from 3 mm to 35 mm diameter), and biofeedback-assisted muscle re-education using surface electromyography (sEMG). Second-line pharmacological adjuncts include topical lidocaine gel, vaginal diazepam suppositories (5–10 mg), and — in refractory cases — intramuscular or intravaginal onabotulinumtoxinA (Botox®, 50–200 units) injection under sedation. Mindfulness-based stress reduction (MBSR) protocols are increasingly integrated. With this evidence-based hierarchy, surgical intervention is rarely indicated and reserved for concomitant anatomical pathology such as an imperforate hymen.
Candidates
• ELIGIBLE PATIENTS:
• Women of any age presenting with Grade 1–5 vaginismus per Lamont Classification, including primary (lifelong) and secondary (acquired) subtypes
• Patients with confirmed Genito-Pelvic Pain/Penetration Disorder (GPPPD) per DSM-5 criteria, validated by a licensed gynecologist or psychosexual medicine specialist
• Patients who have not responded to self-directed dilator therapy alone and require supervised, structured clinical programs
• Patients seeking botulinum toxin A (BoNT-A) injection for refractory vaginismus who are medically stable and not pregnant or breastfeeding
• Patients with concurrent provoked vestibulodynia, lichens sclerosus, or pelvic floor dysfunction as a contributing factor, suitable for integrated treatment
• Partners of patients willing to participate in couples therapy components where clinically indicated (enhances outcomes significantly)
• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL:
• Gynecological pelvic examination report (or telehealth assessment where physical exam is not tolerated) with Lamont Grade documented
• Vaginal swab culture to exclude active bacterial vaginosis, candidiasis, or STI as a confounding etiology
• Pelvic floor sEMG biofeedback baseline assessment (if previously performed) — records to be shared with receiving clinician
• Psychological/psychosexual health screening report (e.g., PHQ-9 for depression, GAD-7 for anxiety) from a qualified mental health professional
• Pelvic ultrasound (transabdominal preferred where transvaginal is not tolerated) to exclude structural uterine or ovarian pathology
• Complete blood count (CBC) and basic metabolic panel if sedation-assisted botulinum toxin injection is anticipated
• Allergy history, particularly to botulinum toxin, aminoglycosides, or topical anesthetic agents
• CONTRAINDICATIONS:
• Active pelvic or vaginal infection (must be treated and resolved prior to initiation of dilator or injection therapy)
• Pregnancy (botulinum toxin injection is absolutely contraindicated; behavioral therapy may continue under obstetric guidance)
• Breastfeeding (BoNT-A injection contraindicated)
• Known hypersensitivity to botulinum toxin or its excipients (human albumin, sodium chloride)
• Neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) — absolute contraindication to BoNT-A
• Uncontrolled severe psychiatric disorder that prevents engagement with CBT or behavioral protocols (requires stabilization first)
• Anatomical cause requiring surgical correction (e.g., imperforate hymen, vaginal septum) — these must be surgically resolved before vaginismus-specific rehabilitation begins
Procedure
TIER 1 — FIRST-LINE BEHAVIORAL AND PHYSIOTHERAPY PROTOCOLS (Non-Pharmacological):
Structured Pelvic Floor Physical Therapy: The cornerstone of vaginismus treatment, delivered by specialist women's health physiotherapists. Techniques include manual internal pelvic floor release (trigger-point therapy targeting the pubococcygeus, iliococcygeus, and obturator internus), connective tissue mobilization, and paradoxical relaxation training. Sessions are typically 45–60 minutes, conducted 2–3 times per week over 4–12 weeks depending on severity grade.
Progressive Vaginal Dilator Therapy: Systematic desensitization using a calibrated set of medical-grade silicone dilators (commonly 6-piece Amielle Comfort® or equivalent sets, progressing from approximately 3 mm to 35 mm diameter). Patients progress through sizes at their own controlled pace under physiotherapist supervision, with homework assignments for daily home practice. The average program spans 6–12 weeks for Grades 1–3 and 12–24 weeks for Grades 4–5.
sEMG Biofeedback-Assisted Relaxation Training: Surface electromyography sensors placed at the perineum or intravaginally (where tolerated) provide real-time visual or auditory feedback of pelvic floor muscle activation levels. Patients learn to consciously identify and down-regulate hypertonicity, achieving resting tone targets below 2 µV. This technology-assisted approach significantly accelerates voluntary muscle control compared to unassisted exercises.
Cognitive-Behavioral Therapy (CBT) and Psychosexual Counseling: Delivered by licensed psychosexual therapists, addressing catastrophizing cognitions, fear-avoidance cycles, trauma histories (including sexual trauma, religious/cultural conditioning, or prior painful medical experiences), and relationship dynamics. ACT (Acceptance and Commitment Therapy) and EMDR (Eye Movement Desensitization and Reprocessing) are utilized for trauma-related presentations. Couples sessions are integrated where applicable.
TIER 2 — PHARMACOLOGICAL ADJUNCTS:
Topical Anesthetics: 2% lidocaine gel or EMLA cream (lidocaine 2.5% / prilocaine 2.5%) applied to the vestibular region 10–15 minutes prior to dilator use to reduce initial pain and break the pain-spasm-pain cycle, facilitating progression.
Vaginal Diazepam Suppositories: Compounded vaginal diazepam (2–10 mg) used 30–60 minutes before dilator therapy sessions. Acts on GABA-A receptors in local pelvic floor musculature to reduce involuntary spasm. Used as a short-term bridge, not a long-term solution.
OnabotulinumtoxinA (Botox®) Injection — Refractory Cases: For Grade 4–5 vaginismus or cases where first-line therapy has not achieved sufficient relaxation after 12+ weeks, injection of onabotulinumtoxinA (50–200 units, most commonly 100–150 units) directly into the bilateral levator ani and bulbocavernosus muscles is performed under conscious sedation (IV midazolam ± propofol) or general anesthesia as a day-care procedure. Injection is ultrasound-guided or performed under direct visualization by an experienced gynecologist. The toxin produces targeted, reversible neuromuscular blockade lasting 3–6 months, creating a window during which accelerated dilator therapy can achieve lasting behavioral re-training. Multiple studies (including Ghazizadeh & Nikzad, 2004; Pacik et al., 2012) report success rates of 75–90% for BoNT-A combined with structured post-injection physiotherapy. The procedure takes approximately 20–30 minutes; patients recover for 2–4 hours post-sedation and are discharged the same day.
Other Pharmacological Support: Low-dose SSRIs (e.g., escitalopram 5–10 mg) or buspirone may be prescribed by the psychiatry liaison for concurrent anxiety disorders. Hormonal causes of vulvovaginal atrophy (e.g., post-partum, post-menopausal) contributing to secondary vaginismus are treated with topical estradiol cream (Vagifem®) or ospemifene (a SERM).
TIER 3 — SURGICAL (Rare, for Anatomical Co-pathology Only): Hymenectomy or vaginal septum resection may be performed laparoscopically or under direct visualization where a structural physical obstruction coexists with conditioned vaginismus. This is not a treatment for vaginismus itself and carries the risk of worsening conditioned spasm if not combined with pre- and post-operative psychophysical rehabilitation.
Cost of Vaginismus Treatment: India vs. UAE
The cost of vaginismus treatment varies significantly depending on the treatment modality selected (behavioral-only program versus botulinum toxin injection under sedation with full physiotherapy integration), the number of sessions required (which correlates with Lamont Grade severity), and the destination chosen. India offers the same clinical evidence base and internationally accredited care at 40–60% of UAE pricing, making it the preferred destination for patients prioritizing affordability without compromising outcomes. The UAE offers premium hospital environments, shorter travel times from Europe, Africa, and the Gulf region, and seamless access for patients who cannot obtain an India e-Medical Visa. All costs below are in USD and represent full program packages as coordinated by GAF Healthcare, including clinical sessions, facility fees, and standard medications.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $800 – $3,500 | ~51% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $1,800 – $7,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL (4–8 Weeks Before Travel):
• GAF Healthcare assigns a dedicated female case manager (bilingual in patient's language) who reviews all submitted medical records, pelvic floor assessments, and psychological screening reports
• Virtual teleconsultation arranged with the receiving gynecologist and pelvic floor physiotherapist for initial clinical assessment and treatment plan confirmation
• Treatment modality confirmed: behavioral-only program (no sedation required) vs. botulinum toxin injection pathway (requires anesthesia clearance)
• Pre-travel checklist issued: cessation of anticoagulants 7 days before BoNT-A injection, vaginal infection screening results, consent forms
• e-Medical Visa application initiated for India (processing 3–5 business days) or UAE entry visa facilitated
• Accommodation and airport transfer arrangements confirmed
PHASE 2 — ARRIVAL AND INITIAL ASSESSMENT (Day 1–2):
• Airport pickup by GAF Healthcare representative; transfer to partner hotel or hospital guesthouse
• Day 1: Registration, clinical intake, and in-person examination by gynecologist (Lamont Grade confirmed or revised)
• Pelvic floor physiotherapy baseline sEMG assessment performed
• Day 2: Psychosexual counselor intake session; treatment schedule formalized
• First dilator therapy orientation session with physiotherapist in a private, dedicated therapy room
PHASE 3 — ACTIVE TREATMENT PROGRAM (Week 1–3, or as individually determined):
• FOR BEHAVIORAL/PHYSIOTHERAPY PATHWAY (Grades 1–3): Intensive outpatient program of daily physiotherapy sessions (45–60 min), alternate-day CBT/psychosexual counseling sessions, and structured home dilator practice with app-based progress tracking. Typical intensive program: 10–15 in-person sessions over 2–3 weeks. Partners may participate in designated couples sessions.
• FOR BOTULINUM TOXIN INJECTION PATHWAY (Grades 4–5 / Refractory): Day-care procedure performed on Day 3 or 4. Patient fasts for 6 hours, IV cannula placed, conscious sedation or short GA administered. Gynecologist injects BoNT-A (100–150 units) into levator ani bilaterally under ultrasound guidance. Total procedure time: 20–30 minutes. Recovery in day-care unit: 2–3 hours. Patient discharged same day. Physiotherapy dilator program begins 48–72 hours post-injection (once initial muscle relaxation onset is perceptible). 8–12 intensive physiotherapy sessions follow over 10–14 days.
PHASE 4 — RECOVERY AND DISCHARGE MILESTONES:
• Milestone 1 (Day 3–5 post-BoNT-A, or Week 1 behavioral): Successful independent insertion and comfortable retention of dilator size 2–3 without pain or significant anxiety
• Milestone 2 (Day 7–10): Progress to dilator sizes 4–5; biofeedback resting EMG tone consistently below 3 µV
• Milestone 3 (Day 10–14 / Week 2–3): Patient can self-manage dilator program independently; anxiety scores (GAD-7) reduced by ≥4 points from baseline; discharge physiotherapy plan finalized
• Fit-to-fly clearance issued by treating gynecologist once milestones 1–3 are met
• Comprehensive clinical summary, dilator progression chart, home exercise program, and telehealth follow-up schedule provided
PHASE 5 — REMOTE FOLLOW-UP (Weeks 4–12 Post-Discharge):
• Weekly telehealth check-ins with GAF Healthcare case manager for first 4 weeks
• Fortnightly video consultations with physiotherapist and psychosexual counselor for weeks 4–12
• BoNT-A patients: follow-up consultation at 6 weeks to assess muscle tone and treatment response; plan for potential second injection if needed (typically 15–20% of patients require one additional session)
• 3-month outcome assessment using validated Patient Global Impression of Improvement (PGI-I) scale and Female Sexual Function Index (FSFI)
Risks & Considerations
Vaginismus treatment is exceptionally safe when delivered by a trained multidisciplinary team; however, patients must be counseled honestly about the following specific risks and considerations:
For behavioral and physiotherapy protocols: The primary risk is psychological distress during exposure-based desensitization, particularly in patients with unresolved sexual trauma. A small percentage of patients (approximately 5–10%) may experience transient worsening of anxiety or intrusive symptoms when beginning dilator therapy without adequate psychological preparation; this underscores the necessity of concurrent psychosexual counseling. Physical injury from dilator misuse (mucosal abrasion, minor bleeding) is rare but possible if progression is forced beyond the patient's readiness — structured physiotherapist supervision mitigates this risk substantially. Relapse following completion of the program occurs in approximately 10–20% of cases, most commonly precipitated by a new stressful life event, relationship change, or new painful pelvic experience; booster sessions are typically effective.
Top Hospitals for Vaginismus Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Vaginismus Treatment
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Vaginismus Treatment
The total cost of a comprehensive vaginismus treatment program — encompassing initial clinical assessment, pelvic floor physiotherapy sessions, psychosexual counseling, biofeedback-assisted therapy, and dilator therapy materials — ranges from approximately USD $800 to $3,500 in India, depending on the severity of the condition (Lamont Grade 1–5), the number of sessions required, and whether botulinum toxin A (Botox®) injection under sedation is included. In the UAE (Dubai or Abu Dhabi), the equivalent program costs between USD $1,800 and $7,000. The higher UAE pricing reflects premium hospital infrastructure, DHA-regulated staffing ratios, and the higher cost-of-living environment; the clinical evidence base and treatment protocols are equivalent across both destinations. Both India and the UAE offer internationally accredited care — NABH- and JCI-accredited centers in India, and JCI- and DHA-licensed hospitals in the UAE. For patients who require botulinum toxin injection under sedation specifically, the procedure-only cost (excluding the full physiotherapy program) is approximately USD $500–$1,200 in India and USD $1,200–$2,500 in the UAE. GAF Healthcare provides transparent, itemized cost estimates based on each patient's specific Lamont Grade, treatment plan, and desired destination before any commitment is made.
The required in-country duration before safe international air travel depends entirely on the treatment modality prescribed for your severity grade. For patients undergoing a behavioral and physiotherapy-only program (typically Lamont Grades 1–3), an intensive in-person program of 10–15 sessions can be completed within 2–3 weeks, after which fit-to-fly clearance is issued by the treating gynecologist. There are no physical restrictions on flying for this cohort; the primary consideration is ensuring that patients have been trained to fully manage their home dilator program independently and have a remote follow-up structure in place. For patients who undergo onabotulinumtoxinA (Botox®) injection under sedation (typically Grades 4–5 or refractory cases), a minimum in-country stay of 10–14 days post-procedure is recommended. This allows the initial neuromuscular effect to establish (onset begins within 24–72 hours, peak effect at 7–14 days), the early physiotherapy program to begin and reach the first measurable milestones, and a post-procedure gynecological review to confirm safe recovery from sedation and rule out any injection-site complications. Patients are typically cleared to fly 5–7 days post-injection if clinically well, but GAF Healthcare advises a minimum 10-day stay to maximize the therapeutic benefit of the in-person program. Long-haul flights over 6 hours post-sedation are not recommended within the first 5 days as a precautionary standard. Your GAF Healthcare case manager will ensure that your discharge date and flight booking are aligned with your treating physician's fit-to-fly certification.
Vaginismus has among the highest treatment success rates of any sexual health condition when managed with a structured, evidence-based, multidisciplinary approach. Published clinical literature reports overall success rates of 80–95% for integrated programs combining pelvic floor physiotherapy, cognitive-behavioral therapy (CBT), progressive dilator desensitization, and — where indicated — biofeedback and pharmacological adjuncts. For patients undergoing botulinum toxin A (BoNT-A) injection in combination with post-injection physiotherapy and psychosexual counseling, success rates of 75–90% are consistently reported across multiple peer-reviewed trials (including Pacik et al., 2012; Yoon et al., 2021). 'Success' is defined clinically as the ability to achieve comfortable, pain-free vaginal penetration and — in patients who desire it — satisfactory sexual intercourse, alongside a sustained reduction in pelvic floor resting electromyography (EMG) tone and improved scores on validated instruments such as the Female Sexual Function Index (FSFI) and the Patient Global Impression of Improvement (PGI-I) scale. Key factors that positively influence outcomes include earlier treatment initiation (lower Lamont Grade at presentation), full engagement with both the physiotherapy and psychological components of the program, partner participation in couples sessions where applicable, absence of significant unresolved sexual trauma (or concurrent trauma-focused therapy such as EMDR), and consistent adherence to the home dilator practice schedule post-discharge. Factors associated with lower success rates include very high Lamont Grade (4–5), long duration of untreated vaginismus (greater than 5 years), untreated comorbid severe anxiety disorder or PTSD, and programs that address only the physical component without psychological co-treatment. GAF Healthcare's partner centers specifically use integrated multidisciplinary teams to optimize all modifiable predictors of success for each patient.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end logistical coordination to ensure that the non-clinical aspects of international medical travel are fully managed, allowing patients to focus entirely on their recovery:
VISA ASSISTANCE — INDIA: GAF Healthcare's documentation team assists patients in applying for the Indian e-Medical Visa, which is available to citizens of over 150 countries. The application is completed online; the visa is typically granted within 3–5 business days. A formal Medical Invitation Letter from the partner hospital, required as part of the application, is arranged directly by GAF Healthcare. Visa extensions can be facilitated if the treatment program requires a longer stay than initially planned.
VISA ASSISTANCE — UAE (DUBAI / ABU DHABI): Citizens of over 90 countries receive visa-on-arrival or visa-free entry to the UAE for up to 30–90 days. For patients from countries requiring a pre-arranged visa, GAF Healthcare coordinates with its UAE hospital partners to issue a medical visit visa invitation letter and guides patients through the application process. UAE entry procedures are generally streamlined and low-barrier for medical tourists.
AIRPORT TRANSFERS: Private air-conditioned vehicle transfers are arranged for patients and their attendants between the arrival airport and the designated hotel or hospital. All drivers are vetted, and female drivers can be specifically requested for patients who prefer this. Return airport transfers are scheduled in coordination with the patient's fit-to-fly clearance date.
DEDICATED TRANSLATORS: GAF Healthcare provides access to professional medical interpreters for Arabic, Russian, French, Swahili, Bangla, and other languages relevant to its patient population. For vaginismus patients in particular, all translators assigned to therapy sessions are female and trained in medical confidentiality and sensitive clinical communication protocols.
ATTENDANT AND PATIENT ACCOMMODATION: GAF Healthcare has negotiated preferential rates at partner hotels and hospital guesthouses within 5–15 minutes of all treating facilities. Accommodation options range from comfortable 3-star guesthouses to 5-star hotels for patients choosing the UAE. All accommodations include private rooms suitable for one patient and one accompanying attendant, Wi-Fi, dietary support aligned with the patient's medical needs, and 24-hour GAF Healthcare helpline access.
CONFIDENTIALITY AND PRIVACY: Given the sensitive nature of vaginismus treatment, GAF Healthcare enforces strict privacy protocols. All communications, records, and case discussions are handled exclusively by female case managers where requested. Medical records are transmitted only via encrypted, HIPAA-aligned platforms. The treating hospital team is briefed on confidentiality requirements, and no identifiable patient information is shared beyond the direct care team.
CONTINUITY OF CARE COORDINATION: Upon return home, GAF Healthcare shares a complete clinical summary with the patient's local gynecologist or GP, facilitates prescription transfers where legally permissible, and maintains a 90-day post-departure telehealth follow-up schedule with the treating team.